anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a Chinese herbal medicine preparation for treating nasosinusitis, which is formed by preparing xanthium, magnolia flowers, honeysuckle flowers, forsythia fruit, madder, scutellaria roots, houttuynia, herba hedyotis diffusae, giant knotweed rhizomes, dahurian angelica roots, mint, semen coicis, astragalus roots, white atractylodes rhizomes, red peony roots, American ginseng, lilies, radices trichosanthis, lumbricus, tuckahoe, pueraria roots, raw licorice roots, etc. A granule, a pill, a tablet, a capsule and oral liquid can be prepared according to the common technological process. The present invention has the advantages that the local pathogen bodies can be eliminated, the general immunity function can be improved, the disease resistance is improved, and the purposes of taking a temporary solution and effecting a permanent cureare achieved. The present invention contains no hormones or chemicals, and is suitable for old people and infants. The effective treating rate is as high as 84%. The present invention is commonly taken for more or less two months, and a patient can be cured.
A total of 104 subjects with DPN who meet the inclusion criteria will be included in the study. Subjects will be classified as mild, moderate and severe in terms of severity by using the toronto clinical scoring system（TCSS）, and subsequently randomised into the EA group and the waiting list group by using a central randomisation system. The indexes of main outcome evaluation are: sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) of the tibial and peroneal nerves of the lower extremities. The indexes of secondary outcome evaluation are: 1) Overall clinical effectiveness rate; 2) TCSS score; 3) Chinese medicine symptom score; 4) patient's global impression of change (PGIC); 5) regional temperature test; and 6) laboratory tests (glycosylated haemoglobin, fasting blood glucose, and postprandial 2h blood glucose). This study will evaluate the effectiveness of EA in treating DPN and assess the difference in the efficacy of EA in treating patients with DPN of different severity, as well as explore the feasibility of regional temperature as an indicator for assessing the efficacy of DPN. And based on the results, a standardised, effective and convenient EA treatment protocol will be established for promotion.
This is a 1-arm pilot trial. Recruitment will take place via a hospital, the Helen Dowling Institute and self-referral. The target is to include 34 couples (i.e. 68 participants). All participating cancer patients and their partners will be allocated to the couple mindfulness-based cognitive behavioral therapy, provided via internet (couple eMBCT), called 'COMPANION' (in Dutch: 'Samen Minder Moe') Assessments include three questionnaires (i.e. before starting the intervention (T0), after completing the intervention (T1), and 1 month after T1 (T2)). The assessments include also weekly diaries during a period of 17-22 weeks. A subsample of patients (n ≈ 5) and partners (n ≈ 5) as well as the therapists providing the couple eMBCT will participate in final focus groups. The primary objectives of COMPANION study 2 are to determine the acceptability of the couple intervention and the potential efficacy for patient fatigue. Secondary objectives are to examine the feasibility of trial procedures and the potential working mechanisms of the couple intervention.
The present invention is based upon the findings of two large clinical studies to determine the efficacy of daily consumption of the probiotic strain  Bifidobacterium animalis  subsp.  lactis  deposited as DSM 15954 for 4 weeks on abdominal pain in postmenopausal women.  Bifidobacterium animalis  subsp.  lactis  significantly reduced abdominal pain. Accordingly, the present invention relates to a probiotic product comprising  Bifidobacterium animalis  subsp.  lactis  for use in reducing abdominal pain in a postmenopausal woman. The invention further relates to a method for reducing abdominal pain in a postmenopausal woman, the method comprising administering a probiotic product comprising  Bifidobacterium animalis  subsp.  lactis  to the postmenopausal woman.
Uncontrolled hemorrhage arising from surgery or trauma may cause morbidity and even mortality. Therefore, facilitating control of severe bleeding is imperative for health care worldwide. Among diverse hemostatic materials, chitosan (CS) is becoming the most promising material owing to its non-toxic feature, as well as inherently hemostatic performance. However, further enhancing hemostatic property of CS-based materials without compromising more beneficial functions remains a challenge. In this review, representative hemostatic mechanisms of CS-based materials are firstly discussed in detail, mostly including red blood cells (RBCs) aggregation, platelet adherence and aggregation, as well as interaction with plasma proteins. Also, various forms (involving powder/particle, sponge, hydrogel, nanofiber, and other forms) of CS-based hemostatic materials are systematically summarized, mainly focusing on their design and preparation, characteristics, and comparative analysis of various forms. In addition, varied hemostatic applications are described in detail, such as skin wound hemostasis, liver hemostasis, artery hemostasis, and heart hemostasis. Finally, current challenges and future directions of functional design of CS-based hemostatic materials in diverse hemostatic applications are proposed to inspire more intensive researches.
PURPOSE:To prevent the abrasion of a ball catch and to ensure excellent ink delivering properties, by incorporating a salt of N-acylsarcosine in an ink for a ball point pen, comprising a pigment, a resin, a solvent and water and having a particular viscosity. CONSTITUTION:A pigment (A) (e.g., azo pigment) is mixed with a resin (B) (e.g. styrene-maleic resin), a solvent (C) (e.g., ethylene glycol), water (D) and a metal salt and (or) amine salt of N-acylsarcosine to obtain an intended ink compsn. for a ball point pen, having a viscosity of 50-2,000cps. The component E is obtained by neutralizing N-acylsarcosine (e.g., N-lauroylsarcosine) with sodium hydroxide, triethanolamine or the like. A suitable amt. of the component E is about 0.5-7wt% based on the total weight of the ink compsn.
A standard face mask will be used at 8L/minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 60%.
This review examines the reliability of cystatin C as a biomarker for kidney function in paediatric populations. Chronic kidney disease (CKD) affects a significant number of children globally, leading to severe health complications such as anaemia, hypertension, and growth disorders. Traditionally, kidney function has been assessed using the estimated glomerular filtration rate derived from serum creatinine, though this method is flawed due to variability in muscle mass, age, gender, and diet. Cystatin C offers an alternative as it is less influenced by these factors. Evidence from various studies indicates that cystatin C provides a more accurate assessment of kidney function, especially in neonates and children with urinary tract malformations. Additionally, it is more reliable in early detection of acute kidney injury in paediatric intensive care units. Despite its potential, cystatin C is not yet widely adopted in clinical guidelines, primarily due to a lack of large-scale paediatric studies. Nonetheless, existing research supports its utility in providing a consistent and precise measure of kidney function across different paediatric age groups, suggesting that it could enhance early diagnosis and management of CKD in children if more extensive validation studies are conducted.
Hypermutator lineages of Pseudomonas aeruginosa arise frequently during the years of airway infection experienced by patients with cystic fibrosis and bronchiectasis but are rare in the absence of chronic infection and structural lung disease. Since the onset of the COVID-19 pandemic, large numbers of patients have remained mechanically ventilated for extended periods of time. These patients are prone to acquire bacterial pathogens that persist for many weeks and have the opportunity to evolve within the pulmonary environment. However, little is known about what types of adaptations occur in these bacteria and whether these adaptations mimic those observed in chronic infections. We describe a COVID-19 patient with a secondary P. aeruginosa lung infection in whom the causative bacterium persisted for >50 days. Over the course of this infection, a hypermutator lineage of P. aeruginosa emerged and co-existed with a non-hypermutator lineage. Compared to the parental lineage, the hypermutator lineage evolved to be less cytotoxic and less virulent. Genomic analyses of the hypermutator lineage identified numerous mutations, including in the mismatch repair gene mutL and other genes frequently mutated in individuals with cystic fibrosis. Together, these findings demonstrate that hypermutator lineages can emerge when P. aeruginosa persists following acute infections such as ventilator-associated pneumonia and that these lineages have the potential to affect patient outcomes.IMPORTANCEPseudomonas aeruginosa may evolve to accumulate large numbers of mutations in the context of chronic infections such as those that occur in individuals with cystic fibrosis. However, these "hypermutator" lineages are rare following acute infections. Here, we describe a non-cystic fibrosis patient with COVID-19 pneumonia who remained mechanically ventilated for months. The patient became infected with a strain of P. aeruginosa that evolved to become a hypermutator. We demonstrate that hypermutation led to changes in cytotoxicity and virulence. These findings are important because they demonstrate that P. aeruginosa hypermutators can emerge following acute infections and that they have the potential to affect patient outcomes in this setting.
Serious psychiatric adverse experiences have been reported in patients treated with SUSTIVA. In controlled trials of 1008 patients treated with regimens containing SUSTIVA for a mean of 2.1 years and 635 patients treated with control regimens for a mean of 1.5 years, the frequency (regardless of causality) of specific serious psychiatric events among patients who received SUSTIVA or control regimens, respectively, were severe depression (2.4%, 0.9%), suicidal ideation (0.7%, 0.3%), nonfatal suicide attempts (0.5%, 0), aggressive behavior (0.4%, 0.5%), paranoid reactions (0.4%, 0.3%), and manic reactions (0.2%, 0.3%). When psychiatric symptoms similar to those noted above were combined and evaluated as a group in a multifactorial analysis of data from Study 006, treatment with efavirenz was associated with an increase in the occurrence of these selected psychiatric symptoms. Other factors associated with an increase in the occurrence of these psychiatric symptoms were history of injection drug use, psychiatric history, and receipt of psychiatric medication at study entry; similar associations were observed in both the SUSTIVA and control treatment groups. In Study 006, onset of new serious psychiatric symptoms occurred throughout the study for both SUSTIVA-treated and control-treated patients. One percent of SUSTIVA-treated patients discontinued or interrupted treatment because of one or more of these selected psychiatric symptoms. There have also been occasional postmarketing reports of death by suicide, delusions, and psychosis-like behavior, although a causal relationship to the use of SUSTIVA cannot be determined from these reports. Patients with serious psychiatric adverse experiences should seek immediate medical evaluation to assess the possibility that the symptoms may be related to the use of SUSTIVA, and if so, to determine whether the risks of continued therapy outweigh the benefits. See Adverse Reactions  (6.1).
PURPOSE:To obtain the titled composite, by treating a tissue of a living body with a proteolytic enzyme, and including a drug in the produced tissue carrier. CONSTITUTION:A tissue carrier originated from a living body (e.g. ureter, deferent duct, gullet, trachea, vein, etc. of monkey, rat, dog pig, etc.) is treated with a proteolytic enzyme (e.t. ficin), and a drug (any kind of drugs suitable to be released slowly, e.g. carcinostatic agent, hormone preparation, antihistaminic agent, hypotensor, etc.) is included in the processed tissue to obtain the objective drug-containing slow-releasing composite. The filling of the drug is carried out in dry state attained, e.g. by freeze-drying. A crosslinked structure can be developed in the tissue carrier and the biocompatibility of the tissue can be improved, by irradiating the tissue carrier with light or ionizing radiation. By properly controlling the irradiation dose, a degraded structure is formed in the tissue carrier to effect the digestion of the tissue, and when the tissue is irradiated with radiation having high transmittance, even the inner part of the tissue carrier can be sterilized sufficiently and the inflammation reaction is suppressed.
Patients receive radium-223 dichloride IV as in Arm A and peposertib PO QD or BID as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 15 of cycles 2-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, and CT or MRI throughout the study.
Studies in the literature show that humanistic care perception should develop as a student. At this point, it is of great importance to know the competency level of nursing students regarding humanistic care. Although the evaluation of competency and professional development is an important point in nursing education, the difficulty of defining the concept of competency reveals the need for measurement tools. A valid and reliable scale is needed to be used in measuring the humanistic care competencies of nursing students. Reliable measurement of humanistic care competency in nursing students will guide the education curriculum. This study is an original study in its field as it is the development of a scale measuring competency regarding humanistic care.
Patients with thrombotic antiphospholipid syndrome (APS) are at high risk for recurrent thrombosis, and indefinite anticoagulation is recommended. Patients with APS merit indefinite anticoagulation, and vitamin K antagonists (VKAs) have historically been the standard treatment. Direct oral anticoagulants (DOACs) present an appealing alternative to VKAs. Due to their pharmacokinetic and pharmacodynamic characteristics, DOACs offer advantages over VKAs, namely the lack of need for laboratory monitoring, the usage of a fixed dosage, and the absence of significant interaction with dietary components and drugs. The efficacy and safety of DOACs in patients with APS have been studied in four phase II/III clinical trials (three with rivaroxaban and one with apixaban). These studies showed DOACs' inferiority compared to VKAs in preventing recurrent thrombosis. Recurrence was significantly greater in patients with arterial thrombotic events and a triple positivity for antiphospholipid antibodies. No differences were observed in the incidence of venous thromboembolism between both groups. Major bleeding was similar in patients treated with DOACs or VKAs. Several observational studies have reported similar results. This review aims to analyse the existing evidence on the efficacy and safety of DOACs for secondary prevention in patients with APS.
The invention relates to preparation of a receptor targeted nano metal organic framework and an application of the preparation. The invention aims at solving the problems that the existing carrier is low in drug loading rate and poor in targeting. The preparation method provided by the invention comprises the following steps: 1, preparing a nano metal organic framework; and 2, preparing a RGD (arginine-glycine-aspartic acid) modified nano metal organic framework. The receptor targeted nano metal organic framework provided by the invention is applied in drug carriers. The synthesis route of an organic metal framework is changed to prepare the nano metal organic framework having the advantages of nano carriers; when being used as a drug carrier, the RGD modified nano metal organic framework has good targeting and large drug loading rate, the carrier of the receptor targeted nano metal organic framework is loaded by means of the adsorption property of specific surface area of a mesoporous carrier, and the loading quantity can reach 50%. The receptor targeted nano metal organic framework provided by the invention is applied in the pharmaceutical field.
The invention discloses an anti-CTLA-4 nanobody Nb36 as well as a preparation method and application thereof. The nanobody provided by the invention comprises a complementarity-determining region and a framework region; the complementarity-determining region of the nanobody consists of CDR1, CDR2 and CDR3; the amino acid sequence of CDR1 is that of a 26th-32nd amino acid of SEQ ID No. 5 in a sequence table; the amino acid sequence of CDR2 is that of a 48th-55th amino acid of SEQ ID No. 5 in the sequence table; the amino acid sequence of CDR3 is that of a 94th-112th amino acid of SEQ ID No. 5 in the sequence table. The nanobody Nb36 can be combined to T cells and CTLA-4, can be used for research and development of a CTLA-4 molecular detection reagent, and can be used for preparing a tumor inhibitor or a tumor cell inhibitor and preparing drugs for inhibiting CTLA-4 activity and promoting proliferation of the T cells.
Participants in the NC condition will also provide CO levels twice-daily. However, their reinforcement will not be contingent upon their CO level but will be yoked to someone in the CM condition so that average reinforcer values are equivalent across the 2 conditions.
PROBLEM TO BE SOLVED: To obtain a new compound having a low toxicity, and useful as a medicine, especially as a coccidiostat, a nematocide or antibacterial agent used for human or an animal. SOLUTION: This polyether-based compound is a compound of formula I [Me is methyl; R is H, a (substituted)alkyl, a (substituted) alkenyl or the like; X is O, S, NR1 group or the like; R1 is H, a (substituted)alkyl, a (substituted) alkenyl or the like]. The compound of formula I is obtained e.g. as a preferable production method, by using (A) a compound of formula II or its salt (e.g.; a compound of formula III) with (B) a compound of the formula: HX-R (e.g.; benzyl alcohol) in preferably stoichiometric amount to an excess amount of the component B based on the component A, as necessary in the presence of a base such as anhydrous cesium carbonate at preferably 0-100 deg.C for 1 hr to 10 days.
FIELD: personal demand items. ^ SUBSTANCE: cake soap includes at least two different fractions, solubility of which differs at least by 1.0%. Fraction A is less soluble and contains: soaps, one or more fatty acids C12-C20 with straight or ramified chain, hardener and water, and fraction B is more soluble in water compared to fraction A, and contains: soaps, component that increases solubility and is selected from group, including: moisturiser, spirit, moisturiser that is a saccharide, synthetic surfactant that is not soap, or their mixtures; hardener, one or more fatty acids C12-C20 with straight or ramified chain and water. All components are taken at a certain ratio. ^ EFFECT: production of soap with massaging and peeling effect. ^ 9 cl, 5 ex
BACKGROUND: Adequate skill levels of gross motor capacity affect activities of daily living, participation in recreational activities and general physical activity levels of youths (7-21 years). Most studies of typically developing youths have reported significant negative relationships between gross motor capacity and body mass index. The latter findings are especially of concern for youths with intellectual disabilities in that it has been estimated that 61% of children and 66% of adolescents were classified as overweight/obese. Therefore, the purpose of this study was to determine the strength of the relationship between body mass index and gross motor capacity among youths with mild to moderate intellectual disability (ID).
METHODS: Components of the Bruininks-Oseretsky Test of Motor Proficiency (BOT-2) were used for designated aspects of gross motor capacity: six items for upper limb coordination (ULC); seven items for balance (BAL); six items for bilateral coordination (BLC); and one item for agility (A-2). Participants consisted of 654 youths (438 men), ages 8-21 years with ID. Participants were divided into pre-puberty and post-puberty men (post ≥12 years) and women (post ≥10 years of age). Body mass index (BMI, kg/m2) was determined by height and weight measurements on the day of testing. A Kendall's tau correlation coefficient (τ) was used to determine the strength of the relationship between body mass index and gross motor capacity (BOT-2 test scores).
RESULTS: The τ values for both pre-puberty and post-puberty for all BAL, BLC, A-2 tests and for three of the six ULC tests were negligible to very weak (τ = 0 to ±0.19). Higher τ values were seen for pre-puberty youths in three of the ULC tests, but they fell within the weak range (τ < 0.24). When combining all pre-puberty and post-puberty participants, τ values were in the negligible to very weak range for all tests.
CONCLUSION: The strength of relationship between body mass index and gross motor capacity as measured by the BOT-2 subtest item scores used in this study is very weak and suggests that they are not clinically relevant.
PURPOSE: A composition containing an inhibitor for TMEM 126A expression or activation for preventing and treating hypersensitive immune diseases is provided to induce apoptosis of immunocytes. CONSTITUTION: A pharmaceutical composition for preventing and treating hypersensitive immune diseases contains an inhibitor for TMEM 126A expression or activation. The TMEM 126A has an amino acid sequence of sequence number 1 or 2. The inhibitor for TMEM 126A expression is an antisense nucleotide which complementarily binds to TMEM 126A mRNA, short interfering RNA, or short hairpin RNA. The inhibitor for TMEM 126A activation is a compound, peptide, peptide mimetics, aptamer, or antibody which complementarily binds to TMEM 126A. A method for screening a candidate material for preventing and treating hypersensitive immune disease comprises: a step of treating a test material to a cell line in which TMEM 126A protein is expressed; a step of measuring TMEM 126A expression level in the cell line; and a step of selecting test material in which expression level is reduced comparing with a control group.
TAK-164 0.004 milligram per kilogram (mg/kg) starting dose, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. Dose escalation will be performed to determine the MTD and/or RP2D.
Late infantile or juvenile onset for GM1 or GM2 Gangliosidosis. The study anticipates to include a total of approximately 35 patients.
The other half will be randomized to placebo for 6 months. The placebo pills also start out with one "15mg) pill qday and are increased to 2 tablets ("30mg") qday after 4 weeks if no adverse effects are noted by study physician.
Those in the STRIPE group will complete two power and one strength training sessions a week. All participants will be provided an educational pamphlet and exercises will be divided into four components - hip abductors, hip extensors, core, and quadriceps muscles. The load magnitude will be greater than 60% of the 1RM, with the goal of continually loading against heavy resistance. Participants will complete 4 sets of 6 repetitions, with 3-5 minutes of rest between sets. Time under tension will be prescribed as \<1 second for the concentric phase and 1 second for the eccentric phase of the exercise. The strength training sessions will adhere to same parameters as the SOC. Hip abductor, hip extensor, and core exercises will be initiated during week 1 and continued for the 6-week intervention, while quadriceps focused exercises will be introduced in weeks 3-6.